The association between gut butyrate‐producing bacteria and non‐small‐cell lung cancer

Abstract

Background Recently, it has been found that the gut microbiota may affect the development of lung cancer through the “gut‐lung axis.” To investigate this relationship, we performed this study to determine whether the gut microbiota in non‐small‐cell lung cancer (NSCLC) patients is different from that in healthy adults. Methods Quantitative PCR (qPCR) was used to detect the expression levels of eight gut butyrate‐producing bacteria in healthy adults and NSCLC patients. We enrolled 30 patients with NSCLC and 30 subjects from 100 healthy adults after matching for age and sex. Results Compared to healthy adults, most of the gut butyrate‐producing bacteria in NSCLC patients were significantly decreased; these included Faecalibacterium prausnitzii , Clostridium leptum , Clostridial cluster I , Ruminococcus spp., Clostridial Cluster XIVa , and Roseburia spp. Among the gut butyrate‐producing bacteria, we analyzed Clostridial cluster IV and Eubacterium rectale were not decreased in NSCLC patients. Conclusions We conclude that NSCLC patients had gut butyrate‐producing bacteria dysbiosis. Further studies should be performed to investigate the underlying mechanisms of how these specific bacteria affect lung cancer progression and prognosis.

The Effects of Prebiotic Supplementation with OMNi-LOGiC® FIBRE on Fecal Microbiome, Fecal Volatile Organic Compounds, and Gut Permeability in Murine Neuroblastoma-Induced Tumor-Associated Cachexia

“…The reduction of butyrate-producing Eubacterium and Roseburia confirms reports demonstrating reduced relative abundances of these bacteria in patients with prostate or colorectal cancer [ 43 , 44 ]. The findings concerning Ruminococcus contradict reports of decreased abundances in patients with non-small cell lung or colorectal cancer [ 45 , 46 ]. Studies concerning Muribaculum are restricted to a murine model reporting its decreased relative abundance in SHIP-deficient mice with inflammatory bowel disease [ 47 ].…”

Bidirectional interaction between intestinal microbiome and cancer: opportunities for therapeutic interventions

“…In non-small cell lung cancer (NSCLC) patients, butyrate producers such as Faecalibacterium prausnitzii, Clostridium leptum, Clostridial cluster I, Ruminococcus spp., Clostridial cluster XIVa, and Roseburia spp. were significantly reduced [30]. Since butyrate is essential for preserving mucosal homeostasis, reduction of intestinal butyrate producers may imply a compromised intestinal barrier in these patients.…”

A gut butyrate‑producing bacterium <em>Butyricicoccus&nbsp;pullicaecorum</em> regulates short‑chain fatty acid transporter and receptor to reduce the progression of 1,2‑dimethylhydrazine‑associated colorectal cancer

“…The importance of probiotics in the prevention and treatment of CRC has been studied ( 61 ) and there is increasing evidence of the clinical significance of butyrate-producing gut microbes ( 44 , 62 , 63 ). For instance, another butyrate-producing probiotic in the same family of B. pullicaecorum, Clostridium butyricum , has been demonstrated to prevent tumor development in the intestinal barrier ( 64 , 65 ).…”

“…The microbial metabolite SCFAs, including butyrate, are involved in the regulation of intestinal homeostasis and IBD pathogenesis ( 66 ). Dysbiosis leading to reduction in SCFA levels is associated with numerous human diseases, such as stroke and non-small-cell lung cancer ( 62 , 63 , 67 ). Additionally, SCFAs are associated with certain physiological processes, including immune function ( 68 ), anti-inflammatory effects ( 69 ) and glucose homeostasis ( 70 – 72 ).…”